Intrahepatic Cholestasis of Pregnancy (ICP)

Overview

Intrahepatic cholestasis of pregnancy (ICP) is a liver disorder that occurs only during pregnancy. It is characterized by impaired flow of bile acids from liver cells into the bile ducts, leading to a buildup of bile acids in the bloodstream. The condition typically appears in the third trimester, but it can develop earlier or, rarely, persist after delivery.

ICP affects women worldwide, with the highest reported rates in South America, Scandinavia, and parts of Asia. The prevalence varies:

• United States: 0.2–0.5 % of pregnancies.
• United Kingdom: 1–2 % (higher in women of Asian or Indigenous South American ancestry).
• Chile and Norway: up to 5 % of pregnancies.

Although ICP is not life‑threatening for the mother, the elevated bile acids can increase the risk of fetal distress, preterm birth, and stillbirth. Prompt recognition and management are therefore essential.

Symptoms

Symptoms are usually mild to moderate, but they can be distressing. They often appear suddenly and may worsen at night.

• Pruritus (itching) – the hallmark symptom. It typically starts on the palms of the hands and soles of the feet, then may spread to the trunk and arms. The itch is often described as “burning” or “stingy” and is worse after a warm shower or at night.
• Jaundice – yellowing of the skin and eyes occurs in < 10 % of cases and signals more severe disease.
• Dark urine – due to excess bilirubin.
• Pale stools – because bile pigments are not reaching the intestine.
• Fatigue – nonspecific but common in cholestatic conditions.
• Upper‑right abdominal discomfort – occasional dull pain or fullness.
• Elevated liver enzymes – not felt by the patient but detected on labs; can accompany the above symptoms.

If any of these symptoms develop after the 20th week of gestation, especially intense itching without a rash, consider ICP and seek evaluation.

Causes and Risk Factors

Underlying Mechanisms

ICP is thought to result from a combination of genetic, hormonal, and environmental factors that disrupt bile acid transport proteins (e.g., ABCB4, ABCB11). Elevated estrogen and progesterone levels in pregnancy further impair bile flow.

Key Risk Factors

• Genetic predisposition – family history of ICP or other cholestatic liver diseases.
• Previous ICP – recurrence risk is 60–70 % in subsequent pregnancies.
• Maternal age – women over 35 have a slightly higher incidence.
• Multiple gestation – twins or triplets increase hormonal load.
• Ethnicity – higher rates among South Asian, Scandinavian, and Indigenous South American women.
• Liver disease history – underlying hepatitis, gallstones, or non‑alcoholic fatty liver disease may predispose.
• Environmental triggers – exposure to certain pesticides, heavy metals, or high‑fat diets has been suggested, though data are limited.

Diagnosis

Diagnosis relies on clinical suspicion supported by laboratory testing. The following steps are standard:

1. Detailed History and Physical Exam

• Onset, intensity, and distribution of itching.
• Any rash, jaundice, or abdominal pain.
• Previous episodes of ICP or liver disease.

2. Laboratory Tests

Test	Typical Findings in ICP
Serum bile acids	Elevated >10 µmol/L (most clinicians use >10–14 µmol/L as the diagnostic threshold). Levels >40 µmol/L are linked with higher fetal risk.
Alanine aminotransferase (ALT) / Aspartate aminotransferase (AST)	Mild‑to‑moderate elevation (2–5× upper limit of normal).
Alkaline phosphatase (ALP)	Often elevated in pregnancy; a disproportionate rise may suggest cholestasis.
Total bilirubin	Usually normal; may be increased if jaundice is present.

3. Exclusion of Other Causes

Other pruritic skin conditions (e.g., eczema, allergic reactions) and liver diseases (e.g., hepatitis, gallstones) must be ruled out with appropriate tests such as hepatitis serologies, abdominal ultrasound, or dermatologic evaluation.

4. Fetal Monitoring

Once ICP is diagnosed, serial non‑stress tests (NST) or biophysical profiles (BPP) are usually started at 32 weeks, with more frequent monitoring if bile acids rise >40 µmol/L.

Treatment Options

The primary goals are to relieve maternal itching, reduce serum bile acids, and lower fetal risk.

1. Medications

• Ursodeoxycholic acid (UDCA) – first‑line therapy. 13–15 mg/kg/day in divided doses can lower bile acids by 30–50 % and improve itching in ~80 % of patients. Meta‑analyses (e.g., Cochrane 2021) support its safety for mother and baby.
• Rifampicin – considered when UDCA is insufficient. Dose 300 mg twice daily; careful hepatic monitoring required.
• Antihistamines (e.g., cetirizine) – provide symptomatic itch relief but do not affect bile acids.
• Topical emollients and cooling gels – adjuncts for comfort.

2. Lifestyle and Supportive Measures

• Warm (not hot) showers; avoid prolonged hot baths.
• Wear loose, breathable clothing to reduce skin irritation.
• Maintain adequate hydration and a balanced diet low in saturated fat.
• Limit alcohol and avoid medications known to exacerbate cholestasis (e.g., certain antibiotics, oral contraceptives).

3. Delivery Planning

Because fetal risk rises with gestational age and bile‑acid level, most obstetric societies (e.g., ACOG, RCOG) recommend scheduled delivery at 37 weeks for mild cases and as early as 36 weeks when bile acids exceed 40 µmol/L or there is rapid rise. Delivery timing should be individualized.

4. Post‑delivery Care

Symptoms usually resolve within 2–4 weeks after birth. Repeat liver function tests and bile‑acid measurements 2 weeks postpartum to confirm normalization.

Living with Intrahepatic Cholestasis of Pregnancy

Daily Management Tips

• Track itching intensity – keep a simple diary (scale 0–10) to discuss with your provider.
• Take UDCA with food – reduces gastrointestinal upset.
• Stay cool – use fans, cool compresses, or cotton‑clad sheets at night.
• Nutrition – focus on high‑fiber fruits, vegetables, lean protein, and whole grains. A dietitian can tailor recommendations.
• Regular prenatal visits – ensure labs are repeated every 1–2 weeks as advised.
• Emotional support – ICP can cause anxiety about the baby’s wellbeing. Counseling, support groups, or talking with a perinatal mental‑health specialist can help.

Work and Travel

Most women can continue normal activities. If itching is severe, consider flexible work hours or short breaks to cool the skin. During travel, bring UDCA tablets, antihistamines, and a cooler bag for medication storage.

Prevention

Because genetics and pregnancy hormones are central, primary prevention is limited. However, the following measures may lower risk for a first episode or recurrence:

• Maintain a healthy weight before conception – obesity is linked with higher cholestasis rates.
• Document any prior ICP in medical records; early screening in subsequent pregnancies.
• Avoid excessive vitamin A supplementation (>10,000 IU/day) and certain herbal remedies lacking safety data.
• Discuss potential medication risks with your obstetrician early in pregnancy.

Complications

If left untreated or poorly controlled, ICP can lead to serious maternal and fetal outcomes.

Maternal

• Severe pruritus affecting sleep and quality of life.
• Vitamin K deficiency → prolonged clotting time (rare).
• Rare progression to acute fatty liver of pregnancy or hepatic rupture.

Fetal/Neonatal

• Preterm birth – up to 25 % in severe cases.
• Fetal distress – non‑reassuring heart rate patterns.
• Meconium‑stained amniotic fluid – associated with higher neonatal respiratory problems.
• Stillbirth – risk increases markedly when serum bile acids >100 µmol/L (estimated 2–5 % vs 0.1 % baseline). This underlies the recommendation for early delivery.
• Neonatal Vitamin K deficiency bleeding (due to reduced placental transfer of bile‑soluble vitamins).

When to Seek Emergency Care

Key Take‑aways

• ICP is a pregnancy‑specific liver disorder marked by itching and elevated bile acids.
• It occurs in 0.2–5 % of pregnancies, with higher rates in certain ethnic groups.
• Ursodeoxycholic acid is the mainstay of treatment; early diagnosis and planned delivery reduce fetal risk.
• Maternal symptoms usually resolve after birth, but close postpartum follow‑up is essential.
• Seek emergency care promptly for concerning symptoms such as severe abdominal pain or decreased fetal movement.

For personalized guidance, always discuss your symptoms, test results, and birth plan with a qualified obstetrician or maternal‑fetal medicine specialist.

---

Sources: Mayo Clinic, American College of Obstetricians and Gynecologists (ACOG), Royal College of Obstetricians and Gynaecologists (RCOG), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), Cochrane Database of Systematic Reviews, The Lancet Gastroenterology & Hepatology (2022).